1-20 of 32
Susan O’Brien
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, Ian Flinn, Susan O’Brien, Jacqueline S. Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Marcio Andrade-Campos, Tapan M. Kadia, James S. Blachly
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4844–4855.
https://doi.org/10.1158/1078-0432.CCR-24-0028
Published: 01 November 2024
View article titled, A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Open the PDF for A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia, Daniele Vallisa, Ryan Jacobs, Susan O'Brien, Andrew P. Grigg, Patricia Walker, Cathy Zhou, Joi Ninomoto, Gabriel Krigsfeld, Constantine S. Tam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4385–4391.
https://doi.org/10.1158/1078-0432.CCR-22-0504
Published: 14 October 2022
View article titled, Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts
Open the PDF for Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts in another window
Includes: Supplementary data
Journal Articles

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. Pagel, Chaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 603–608.
https://doi.org/10.1158/1078-0432.CCR-21-1237
Published: 15 February 2022
View article titled, Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Open the PDF for Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare) in another window
Journal Articles

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff P. Sharman, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O'Brien
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3918–3927.
https://doi.org/10.1158/1078-0432.CCR-19-2856
Published: 03 August 2020
View article titled, Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Open the PDF for Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia

Preetesh Jain, Michael J. Keating, William G. Wierda, Mariela Sivina, Philip A. Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Susan O'Brien, Jan A. Burger
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (9): 2154–2158.
https://doi.org/10.1158/1078-0432.CCR-16-1948
Published: 30 April 2017
View article titled, Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Open the PDF for Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Steven E. Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O'Brien
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1149–1155.
https://doi.org/10.1158/1078-0432.CCR-16-1431
Published: 28 February 2017
View article titled, Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Open the PDF for Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in another window
Includes: Supplementary data
Journal Articles

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calin, Susan O'Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2359–2367.
https://doi.org/10.1158/1078-0432.CCR-15-2476
Published: 12 May 2016
View article titled, Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Open the PDF for Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics in another window
Includes: Supplementary data
Journal Articles

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Katja Karjalainen, Diana E. Jaalouk, Carlos Bueso-Ramos, Laura Bover, Yan Sun, Akihiko Kuniyasu, Wouter H.P. Driessen, Marina Cardó-Vila, Cecilia Rietz, Amado J. Zurita, Susan O'Brien, Hagop M. Kantarjian, Jorge E. Cortes, George A. Calin, Erkki Koivunen, Wadih Arap, Renata Pasqualini
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 3041–3051.
https://doi.org/10.1158/1078-0432.CCR-13-3059
Published: 30 June 2015
View article titled, Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
Open the PDF for Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Michael E. Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng, Hongbo Lu, Mary Ann Richie, Rebecca Garris, Lianchun Xiao, Wenbin Liu, Keith A. Baggerly, Elias Jabbour, Susan O'Brien, Jan Burger, Linda J. Bendall, Deborah Thomas, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-14-2888
Published: 14 June 2015
View article titled, A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Open the PDF for A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Clinical relevance of circulating heat shock protein 70 in acute leukemias

Chen-Hsiung Yeh, Richard Tseng, Susan O'Brien, Alison Hannah, Zeev Estrov, Elihu Estey, Hagop Kantarjian, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B13.
Published: 15 August 2014
View article titled, Clinical relevance of circulating heat shock protein 70 in acute leukemias
Journal Articles

Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases

Maher Albitar, Wanlong Ma, Susan O'Brien, Iman Jilani, Xi Zhang, Hagop Kantarjian, Zeev Estrov, Michael Keating, Francis Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): B52.
Published: 15 August 2014
View article titled, Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases
Journal Articles

A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors

Muhammad Wasif Saif, Chris Takimoto, Monica Mita, Udai Banerji, Nicole Lamanna, Januario Castro, Susan O'Brien, Christopher Stogard, Daniel Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 445–455.
https://doi.org/10.1158/1078-0432.CCR-13-1257
Published: 16 January 2014
View article titled, A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
Open the PDF for A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy

Yue Wei, Tapan Kadia, Weigang Tong, Ming Zhang, Yu Jia, Hui Yang, Yumin Hu, Francesco Paolo Tambaro, Jean Viallet, Susan O'Brien, Guillermo Garcia-Manero
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 3923–3932.
https://doi.org/10.1158/1078-0432.CCR-10-0032
Published: 28 July 2010
View article titled, The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy
Open the PDF for The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy in another window
Includes: Supplementary data
Journal Articles

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

Wanlong Ma, Hagop Kantarjian, Benjamin Bekele, Amber C. Donahue, Xi Zhang, Zhong J. Zhang, Susan O'Brien, Elihu Estey, Zeev Estrov, Jorge Cortes, Michael Keating, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3820–3826.
https://doi.org/10.1158/1078-0432.CCR-08-3034
Published: 01 June 2009
View article titled, Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
Open the PDF for Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Aaron D. Schimmer, Susan O'Brien, Hagop Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis Giles, Andre Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel-Reid, Mark Berger, Jean Viallet, Gautam Borthakur
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8295–8301.
https://doi.org/10.1158/1078-0432.CCR-08-0999
Published: 15 December 2008
View article titled, A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Open the PDF for A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies in another window
Journal Articles

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3906–3915.
https://doi.org/10.1158/1078-0432.CCR-08-0366
Published: 16 June 2008
View article titled, Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Open the PDF for Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis in another window
Journal Articles

The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

Apostolia-Maria Tsimberidou, Hagop M. Kantarjian, Sijin Wen, Susan O'Brien, Jorge Cortes, William G. Wierda, Charles Koller, Sherry Pierce, Mark Brandt, Emil J. Freireich, Michael J. Keating, Elihu H. Estey
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 721–730.
https://doi.org/10.1158/1078-0432.CCR-07-2063
Published: 01 February 2008
View article titled, The Prognostic Significance of Serum β<sub>2</sub> Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients
Open the PDF for The Prognostic Significance of Serum β<sub>2</sub> Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients in another window
Journal Articles

Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

John C. Byrd, Susan O'Brien, Ian W. Flinn, Thomas J. Kipps, Mark Weiss, Kanti Rai, Thomas S. Lin, James Woodworth, Dee Wynne, Jennifer Reid, Arturo Molina, Bryan Leigh, Sarah Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4448–4455.
https://doi.org/10.1158/1078-0432.CCR-06-1463
Published: 01 August 2007
View article titled, Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Open the PDF for Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window